<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058509</url>
  </required_header>
  <id_info>
    <org_study_id>N-20180036</org_study_id>
    <nct_id>NCT04058509</nct_id>
  </id_info>
  <brief_title>Clinical Predictors of Extracorporal Shockwave Therapy Efficacy in Patients Presenting With Lateral Hip Pain</brief_title>
  <official_title>Clinical Predictors of Extracorporal Shockwave Therapy Efficacy in Patients Presenting With Lateral Hip Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Canberra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pragmatic clinical trial is considering the variable response to treatment outcome of
      individuals with Greater Trochanteric Pain Syndrome (GTPS). The aim of this study is to
      identify predictors of focused extracorporeal shockwave therapy (fESWT) efficacy in
      individuals with GTPS. Specifically, the ability of clinically applicable measurements
      including: Patient demographics, co-morbidity, oestrogen levels, pain characteristics, hip
      abductor strength, time to pain during single-leg stance test, low back pain, and immediate
      pain reduction to local anaesthetic injection at the trochanter major insertion of Gluteus
      medius (GMed) during walking.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Rating of Change Scale</measure>
    <time_frame>3 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EuroQoL</measure>
    <time_frame>0, 12 and 26 weeks follow-up</time_frame>
    <description>EQ-5D™</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength Static</measure>
    <time_frame>0, 12 and 26 weeks follow-up</time_frame>
    <description>Hip abduction strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Pressure Threshold</measure>
    <time_frame>0, 12 and 26 weeks follow-up</time_frame>
    <description>Lateral hip region</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Specific Functional Scale).</measure>
    <time_frame>0, 6, 12 and 26 weeks follow-up</time_frame>
    <description>difficulties with 1-5 functional tasks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHQ9</measure>
    <time_frame>0, 12 and 26 weeks follow-up</time_frame>
    <description>Severity of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VISA-G</measure>
    <time_frame>0, 12 and 26 weeks follow-up</time_frame>
    <description>disability score for gluteal tendinopathy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>focused shockwave therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 sessions of shock wave treatment.(Focused Shockwave Therapy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Focused shockwave therapy</intervention_name>
    <description>3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.</description>
    <arm_group_label>focused shockwave therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lateral hip pain, worst over the greater trochanter, present for a minimum of 3 months

          -  Age 35-70 years

          -  Female

          -  Pain at an average intensity of ≥3 out of 10 on most days of the last week.

          -  Tenderness on palpation of the greater trochanter

          -  Pain on one of the following:

        Reproduction of pain on 30 sec single leg stand OR Positive Faber test

        Exclusion Criteria:

          -  Any known advanced hip joint pathology where groin pain is the primary complaint
             and/or reproduction of groin pain with Faber or FADDIR.

          -  Where range of pure hip joint flexion is &lt;90°

          -  Radiating pain distal to the Gluteus Max + positive Straight Leg Raise (SLR-test &lt;
             30°)

          -  Known advanced knee pathology or restricted range of knee motion (must have minimum
             90° flexion and full extension)

          -  Any systemic diseases affecting the muscular or nervous system, and uncontrolled
             diabetes

          -  Malignant tumour OR Systemic inflammatory disease

          -  Any factors that would preclude the participant from having an MRI (e.g. pacemaker,
             metal implants, pregnancy, claustrophobia)

          -  If the participant is involved in a legal/workcover or other injury claim

          -  Fear of needles (trypanophobia)

          -  If the participant is unable to write, read or comprehend Danish
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten M Molgaard, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carsten M Molgaard, PhD</last_name>
    <phone>+4523806882</phone>
    <email>cmm@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens Kristinsson, MD</last_name>
    <email>hjk@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten M Molgaard, PhD</last_name>
      <email>cmm@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jens Kristinsson, MD</last_name>
      <email>hjk@rn.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Carsten Møller Poulsen Mølgaard</investigator_full_name>
    <investigator_title>Clinical research physiotherapist</investigator_title>
  </responsible_party>
  <keyword>Greater Trochanter Pain Syndrome</keyword>
  <keyword>Lateral hip pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

